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Bortezomib, an effective anticancer drug for multiple myeloma, often causes peripheral neuropathy
which is mainly characterized by numbness and painful paresthesia. Nevertheless, there is no effective
strategy to escape or treat bortezomib-induced peripheral neuropathy (BIPN), because we have under-
stood few mechanism of this side effect. In this study, we evaluated behavioral and pathological char-
acteristics of BIPN, and investigated pharmacological efﬁcacy of various analgesic drugs and adjuvants on
mechanical allodynia induced by bortezomib treatment in rats. The repeated administration of borte-
zomib induced mechanical and cold allodynia. There was axonal degeneration of sciatic nerve behind
these neuropathic symptoms. Furthermore, the exposure to bortezomib shortened neurite length in PC12
cells. Finally, the result of evaluation of anti-allodynic potency, oral administration of tramadol (10 mg/
kg), pregabalin (3 mg/kg), duloxetine (30 mg/kg) or mexiletine (100 mg/kg), but not amitriptyline or
diclofenac, transiently relieved the mechanical allodynia induced by bortezomib. These results suggest
that axonal degeneration of the sciatic nerve is involved in BIPN and that some analgesic drugs and
adjuvants are effective in the relief of painful neuropathy.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bortezomib is a proteasome inhibitor widely used in chemo-
therapy to treat multiplemyeloma. A side effect of bortezomib is that
it often causes severe peripheral neuropathy and is therefore dose
limiting. Bortezomib-inducedperipheral neuropathy (BIPN) occurs in
35e52% of patients (grade 3 in 8e14% of patients) and is mainly
characterized by hypoesthesia and painful paresthesia (1e3). At
present, themechanismofBIPN isnotwell understoodand there isno
established method to treat it. Thus, the development of peripheral
neuropathy is an important issue in bortezomib chemotherapy.
We previously reported that other anticancer drugs such as
paclitaxel and oxaliplatin induce pain symptoms that are charac-
teristic of neuropathy including mechanical allodynia associatedKyushu University Hospital,
an. Tel.: þ81 92 642 5920;
.jp (N. Egashira).
rmacological Society.
Production and hosting by Elsevie
ons.org/licenses/by-nc-nd/4.0/).with axonal degeneration of the sciatic nerve in rats (4,5). These
anticancer drugs also inhibited neurite outgrowth in cultured rat
pheochromocytoma 12 (PC12) and rat dorsal root ganglion (DRG)
cells. Furthermore, we reported that neurotropin, which attenuated
the inhibition of neurite outgrowth in these cultured cells,
ameliorated neuropathy induced by these anticancer drugs (4,5).
Our ﬁndings indicate that axonal degeneration in the sciatic nerve
is involved in mechanical allodynia induced by paclitaxel and
oxaliplatin, and that the effect on neurite outgrowth has the po-
tential to affect axonal degeneration in sciatic nerve.
It has been reported that administration of bortezomib induces
mechanical and cold allodynia and pathological changes in sciatic
nerve and DRG in rodents (6e9). Recently, it has been revealed a
part of mechanisms of BIPN such as changes the expression of tu-
mor necrosis factor-a (TNF-a), transient receptor potential vanilloid
1 (TRPV1), calcitonin gene-related peptide (CGRP), and substance P
in DRG neurons, and the contributions of peroxynitrite, and altered
discharges of spinal neurons (10e14). Furthermore, bortezomib-
induced mechanical allodynia is inhibited by gabapentin in mice
(15). However, the effects of various analgesic drugs or adjuvants,r B.V. on behalf of Japanese Pharmacological Society. This is an open access article
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animal models of BIPN have been not well studied.
In this study, we developed an animal model of BIPN, and
consequently characterized pain behaviors and pathological
changes. In addition, we investigated the effect of bortezomib on
neurite length in cultured PC12 cells for adequacy evaluation of
bortezomib-induced neurotoxicity. Finally, we evaluated the
pharmacological efﬁcacy of various analgesic drugs and adjuvants
on painful neuropathy.2. Materials and methods
2.1. Animals
Male SpragueeDawley rats weighing 200e250 g (Kyudo Co.,
Tosu) were housed in groups of four to ﬁve per cage, with lights on
from 7:00 to 19:00 h. Animals had free access to food and water in
their home cages. All experiments were approved by the Experi-
mental Animal Care and Use Committee of Kyushu University ac-
cording to the National Institutes of Health guidelines, and we
followed the International Association for the Study of Pain Com-
mittee for Research and Ethical Issues guidelines for animal
research (16).2.2. Drugs
Bortezomib was purchased from LC Laboratories (Woburn, MA,
USA). Tramadol hydrochloride and mexiletine hydrochloride were
purchased from SigmaeAldrich, Inc. (St. Louis, MO, USA). Pre-
gabalin, duloxetine hydrochloride, amitriptyline, and diclofenac
sodium were obtained from Pﬁzer Inc. (New York, NY, USA), Tokyo
Chemical Industry Co., Ltd. (Tokyo), LKT Laboratories, Inc. (St. Paul,
MN, USA), and Novartis International AG (St. Johann, Basel,
Switzerland), respectively. Bortezomib was dissolved in 5%
dimethyl sulfoxide (DMSO, SigmaeAldrich, Inc.) solution. Borte-
zomib (0.05, 0.1, or 0.2 mg/kg) or vehicle (5% DMSO solution) was
administered intraperitoneally (i.p.) twice a week for 2 weeks (on
days 1, 4, 8, and 11). The administration schedule and doses of
bortezomib were determined based on clinical treatment (1.3 mg/
m2 of bortezomib on days 1, 4, 8, and 11). Tramadol, amitriptyline,
and mexiletine were dissolved in sterile water. Pregabalin, dulox-
etine, and diclofenac were suspended in 0.25% sodium carboxy-
methylcellulose (CMC-Na) solution. The volume of vehicle or drug
solution injected was 1 mL/kg.Fig. 1. Effects of bortezomib on body weight (A) and motor coordination (B) in rats. Bor
weight was measured on days 1e5, 8e12, 15e19, and 22e25. The rota-rod test was perfor2.3. Behavioral studies
2.3.1. Rota-rod test
Rota-rod test was performed to investigate the change in
motor coordination. Rats were placed on a rotating rod (Mur-
omachi Kikai Co., Ltd., Tokyo) and the latency to falling was
measured for up to 2 min according to the method described
previously (17). The test was performed three times, and the
rotating speed was 10 rpm.
2.3.2. von Frey test
Mechanical allodynia was assessed by the von Frey test. Each rat
was placed in a clear plastic boxwith awiremesh ﬂoor and allowed
to habituate for 30 min prior to testing. von Frey ﬁlaments (The
Touch Test Sensory Evaluator Set; Linton Instrumentation, Diss,
Norfolk, UK) with a range of 1e15 g bending force were applied to
the mid-plantar skin of each hind paw six times, with each appli-
cation held for 6 s. The paw withdrawal threshold was determined
by a modiﬁed up-down method (4).
2.3.3. Acetone test
Cold allodynia was assessed by the acetone test. Each rat was
placed in a clear plastic box and allowed to habituate for 30 min
prior to testing. Fifty microliters of acetone (Wako Pure Chemical
Industries, Ltd., Osaka) was sprayed onto the plantar skin of each
hind paw, and the number of withdrawal responses was counted
for 40 s from the start of the acetone spray according to the method
described previously (18). The test was performed six times (three
times per hind limb).
2.3.4. Hot-plate test
Thermal hyperalgesia was assessed using a hot-plate test. Each
rat was placed on a hot/cold-plate apparatus (Ugo Basile Biological
Research Apparatus, Gemonio, Varese, Italy), and the latency to
licking their hind paw was measured for up to 60 s. The tempera-
ture of the hot-plate was kept at 52.5 C (19). The test was per-
formed three times.
2.4. Drug evaluation
Mechanical allodynia was conﬁrmed on days 12e15 and drug
evaluation was carried out the next day. Tramadol, pregabalin,
duloxetine, amitriptyline, mexiletine, and diclofenac were admin-
istered orally through a stainless steel gavage tube. Control rats
were injected with the drug vehicle. For tramadol and diclofenac,tezomib (0.05, 0.1, or 0.2 mg/kg) was administered i.p. twice a week for 2 weeks. Body
med on day 15. Results are expressed as mean ± SEM of 10 rats.
Fig. 2. Effects of bortezomib on mechanical allodynia (A), cold allodynia (B), and
thermal hyperalgesia (C) in rats. Bortezomib (0.05, 0.1, or 0.2 mg/kg) was adminis-
tered i.p. twice a week for 2 weeks. The von Frey, acetone, and hot-plate (52.5 C) tests
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istration. For pregabalin, duloxetine, amitriptyline and mexiletine,
the von Frey test was performed every 60 min after drug admin-
istration. Each evaluation was continued until the effects dis-
appeared. The doses and measurement times of these drugs were
chosen based on previous reports (20e24).
2.5. Toluidine blue staining for sciatic nerves
On day 15, sciatic nerves were harvested from rats anesthetized
with isoﬂurane (Mylan, Inc., Canonsburg, PA, USA). Nerves were
immersed in a ﬁxative containing 2% glutaraldehyde at 4 C for 4 h
followed bywashingwith 0.1M phosphate buffer. After 8% sucrose-
substitution, samples were embedded in Epon and sliced, and then
stained with toluidine blue. Sample sections were evaluated by
light microscopy (BX51; Olympus, Tokyo), and analyzed using
ImageJ software version 1.36 (Wayne Rasband, National Institutes
of Health, Bethesda, MD, USA). The g-ratio, myelin sheath thickness
and axonal diameter were analyzed in three ﬁelds of each sample
section from three animals of both groups. The area and circularity
were analyzed in six ﬁelds of each sample section from three ani-
mals of both groups.
2.6. Cell culture
PC12 cells were obtained from RIKEN (Saitama). The cells were
grown in Dulbecco's modiﬁed Eagle's medium (MP Biomedicals,
Inc., Santa Ana, CA, USA) supplementedwith 100 unit/mL penicillin,
100 mg/mL streptomycin, 2 mM L-glutamine, 10% horse serum, and
10% fetal bovine serum (GIBCO BRL, Grand Island, NY, USA). The
cells were cultured at 37 C in air supplemented with 5% CO2 under
humidiﬁed conditions.
2.7. WST-8 assay
Cell viability was assessed by mitochondrial activity measured
by the reduction of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitro
phenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium monosodium salt
(WST-8) to formazan. Twenty-four hours prior to bortezomib
treatment, PC12 cells were seeded onto 24-well plates with 50 ng/
mL recombinant rat b-nerve growth factor (NGF, R&D Systems,
Inc., Minneapolis, MN, USA). The cells were treated with borte-
zomib, and then washed with phosphate buffer saline (PBS) and
incubated with 210 mL serum-free medium and 10 mLWST-8 assay
solution (Cell Counting Kit-8; Dojindo, Kumamoto) for 2 h at 37 C
in humidiﬁed air supplemented with 5% CO2. The incubation
medium was carefully removed and transferred to 96-well plates.
The amount of formazan formed was measured from the
absorbance at 450 nm with a reference wavelength of 620 nm
using a microplate reader (Immuno-Mini NJ-2300; Inter Medical,
Tokyo).
2.8. Assay of PC12 neurite length
PC12 cells were seeded onto 96-well plates with 50 ng/mL NGF
72e96 h prior to bortezomib treatment. The cells were treated with
bortezomib, and then washed with PBS and ﬁxed with 4% para-
formaldehyde for 15 min at room temperature. Cells were blocked
in PBS containing 5% bovine serum albumin (BSA, SigmaeAldrich,
Inc.) for 30 min at room temperature. Acti-stain 488 phalloidinwere performed before the ﬁrst drug administration and on days 4, 8, 11, 15, 18, and 25.
Results are expressed as mean ± SEM of 10e15 rats. *P < 0.05, **P < 0.01 compared
with vehicle.
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diluted (1:1000) with PBS containing 5% BSA and 0.1% Triton X-100
and placed on the cells overnight at 4 C. After washing with PBS,
cells were mounted in 80% glycerol. The nucleus was stained with
40,6-Diamidino-2-phenylindole dihydrochloride (DAPI; Dojindo). F-
actin and nuclear staining were visualized using ImageXpress Mi-
cro XL (Molecular Devices, LLC, Sunnyvale, CA, USA), and neurite
length was measured by analysis software (MetaXpress; Molecular
Devices, LLC).
2.9. Statistical analysis
Data are expressed as the mean ± SEM. Data were analyzed
using the Student's t-test or one-way analysis of variance followed
by the Dunnett's post hoc test to determine differences between
the groups. A probability level of P < 0.05 was accepted as statis-
tically signiﬁcant.
3. Results
3.1. Effects of bortezomib on body weight and motor coordination
in rats
Treatment with bortezomib showed no observable change and
no rats died during the course of the experiment. Compared with
the vehicle group, no signiﬁcant difference in body weight and
motor coordination was observed at any time in the bortezomib-
treated groups (Fig. 1).
3.2. Effects of bortezomib on mechanical allodynia, cold allodynia,
and thermal hyperalgesia in rats
Prior to the ﬁrst bortezomib injection, there were no signiﬁcant
differences in reactivity to mechanical, cold, and thermal stimuli inFig. 3. Histopathology of sciatic nerve in rats treated with vehicle (A) and bortezomib (B
15, sciatic nerve was harvested, and samples were stained with toluidine blue. Photograp
perimeter were measured for calculating g-ratio and circularity. Other parameters were m
sheath thickness; half of (average of (D1 and D2) minus axonal diameter).all groups in any of the von Frey, acetone, or hot-plate tests (Fig. 2).
Bortezomib at a dose of 0.2 mg/kg signiﬁcantly decreased the
withdrawal threshold on days 11 and 15 (P < 0.05; Fig. 2A) and
increased the number of withdrawal responses on days 11 and 15
(day 11: P < 0.01, day 15: P < 0.05; Fig. 2B) compared with the
vehicle group in the von Frey and acetone tests. Conversely, bor-
tezomib did not affect the latency to licking at any time in the hot-
plate test (Fig. 2C).3.3. Histopathology of the sciatic nerve in vehicle and bortezomib-
treated rats
No histological abnormalities in the sciatic nerve were observed
in vehicle-treated rats (Fig. 3A). However, bortezomib (0.2 mg/kg,
i.p.) induced the degeneration of myelinated ﬁbers in the rat sciatic
nerve (Fig. 3B). The circularity of ﬁbers, a quantitative index of
degeneration, was signiﬁcantly decreased in bortezomib-treated
rats compared with vehicle-treated rats (P < 0.05; Table 1). There
were no signiﬁcant differences in axonal area, axonal diameter,
myelin sheath thickness, and g-ratio (the ratio of axon diameter to
total ﬁber diameter) (Fig. 3C).3.4. Effects of bortezomib on cell viability and neurite length in
PC12 cells
No histological abnormalities were observed in vehicle-treated
PC12 cells (Fig. 4A). The exposure to bortezomib (30 and 300 nM)
for 6, 12, or 24 h time dependently shortened the length of neurites
in cultured PC12 cells (6 h: P < 0.05, 12 and 24 h: P < 0.01; Fig. 4B
and D). Moreover, the exposure to bortezomib (30 and 300 nM) for
12 or 24 h signiﬁcantly decreased the cell viability of cultured PC12
cells (30 nM, 12 h: P < 0.05, 24 h: P < 0.01, 300 nM, 12 and 24 h:
P < 0.01; Fig. 4C).). (A, B) Bortezomib (0.2 mg/kg) was administered i.p. twice a week for 2 weeks. On day
hs were originally magniﬁed 1200. Scale bar, 25 mm. (C) Each diameter and axonal
easured as follows. Area; axonal area, axonal diameter; average of d1 and d2, myelin
Table 1
Histopathology of sciatic nerve in rats treated with vehicle and bortezomib.
Vehicle Bortezomib 0.2 mg/kg
Area (mm2) 11.5 ± 0.17 9.14 ± 1.26
Axonal diameter (mm) 4.81 ± 0.26 4.18 ± 0.23
Circularity 0.74 ± 0.01 0.64 ± 0.03*
Myelin sheath thickness (mm) 1.07 ± 0.06 1.04 ± 0.01
G-ratio 0.69 ± 0.01 0.67 ± 0.01
*P < 0.05 compared with vehicle.
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mexiletine, and diclofenac on bortezomib-induced mechanical
allodynia
Bortezomib (0.2 mg/kg, i.p.) signiﬁcantly reduced the paw
withdrawal threshold in the von Frey test compared with vehicle
(P < 0.01; Fig. 5). Tramadol (10 mg/kg, per os (p.o.)), duloxetine
(30 mg/kg, p.o.), and mexiletine (100 mg/kg, p.o.) signiﬁcantly
reversed the reduction of pawwithdrawal threshold by bortezomib
at 60 min after administration in the von Frey test (P < 0.01; Fig. 5A,
C, and E). These effects disappeared 120e240 min after bortezomib
administration. Similarly, pregabalin (3 mg/kg, p.o.) signiﬁcantly
reversed the reduction of pawwithdrawal threshold by bortezomibFig. 4. Effects of bortezomib on cell viability and neurite outgrowth in PC12 cells. Contro
nucleus was stained with DAPI. F-actin and nucleus were visualized by ImageXpress Micro X
were measured using WST-8 assay. The neurite lengths (D) were measured by analysis soft
3e24 h. Results are expressed as mean ± SEM of four experiments. *P < 0.05, **P < 0.01 coat 120 and 180 min after administration in the von Frey test
(120 min: P < 0.05: P < 0.01; Fig. 5B). At 300 min after adminis-
tration this effect of pregabalin had disappeared. Conversely,
amitriptyline and diclofenac did not affect the reduction of paw
withdrawal threshold by bortezomib in the von Frey test (Fig. 5D
and F).4. Discussion
In the present study, we observed mechanical and cold allody-
nia, but not thermal hyperalgesia after bortezomib administration,
which is consistent with previous reports (7,9), and there was no
deterioration in general status. In addition, there was no difference
in change of body weight or motor coordination among the four
groups. It is unlikely that bortezomib-induced mechanical and cold
allodynia are due to changes in body weight, impairment of motor
coordination, or deterioration in general status and the present
model is characterized by both sensory neuropathies (mechanical
and cold allodynia).
In this study, we observed bortezomib (0.2 mg/kg, i.p.) induced
degeneration of myelinated ﬁbers in the rat sciatic nerve. In fact,
there was a signiﬁcant decrease of circularity in the sciatic nerve in
bortezomib-treated rats, indicating that bortezomib inducedl (0.2% DMSO) (A) or bortezomib (300 nM) (B) was exposed to PC12 cells for 24 h. The
L. Photographs were originally magniﬁed 600. Scale bar, 50 mm. The cell viabilities (C)
ware (MetaXpress). PC12 cells were incubated with bortezomib (3, 30 or 300 nM) for
mpared with control.
Fig. 5. Effects of tramadol (A), pregabalin (B), duloxetine (C), amitriptyline (D), mexiletine (E) and diclofenac (F) on bortezomib-induced mechanical allodynia. Rats were
treated with bortezomib (0.2 mg/kg, i.p.) twice a week for 2 weeks. We conﬁrmed the incidence of mechanical allodynia on days 12e15. Tramadol, pregabalin, duloxetine,
amitriptyline, mexiletine, and diclofenac were administered orally. Results are expresses as mean ± SEM of 6e10 rats. **P < 0.01 compared with vehicle, yP < 0.05, yyP < 0.01
compared with control.
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axonal area, axonal diameter, myelin sheath thickness, and g-ratio.
Moreover, we did not observe a change in the number of activating
transcription factor 3 (ATF-3) positive neurons in DRG neurons
(data not shown). Because ATF-3 is a standard marker of neuronal
injury (25), our animal model simulates a neuropathy model that
induces axonal degeneration but not neuronal injury. Some
studies have reported pathological changes in myelinated andunmyelinated axons, mitochondria and endoplasmic reticulum in
Schwann cells in the sciatic nerve of bortezomib-induced neurop-
athy models, and axonal transport dysfunction in primary cultured
DRG cells (6,7,26e29). Additionally, a recent study showed that
bortezomib induced upregulation of ATF-3 in the nuclei of DRG
neurons (8). These studies indicate neuronal injury induced by
bortezomib and these differences may be attributed to the
administration schedule of bortezomib, which was short term in
S. Yamamoto et al. / Journal of Pharmacological Sciences 129 (2015) 43e50 49the model used in the present study. Moreover, we found that
exposure to bortezomib shortened neurite length before decreasing
cell viability in cultured PC12 cells. Therefore, bortezomib may
induce axonal degeneration in the sciatic nerve before inducing
neuronal injury in the long term. In general, axonal degeneration is
known to be responsible for symptoms of neuropathy including
allodynia and hyperalgesia (5,30). Taken together, our results sug-
gest axonal degeneration is involved in the bortezomib-induced
neuropathy in early phase, and that bortezomib induces axonal
degeneration prior to neuronal injury.
Our data indicated single administration of tramadol (10 mg/kg)
and duloxetine (30mg/kg) had anti-allodynic effects on bortezomib-
induced mechanical allodynia. Similarly, these agents have been
reported to exert analgesic effects in animal models of neuropathy
induced by oxaliplatin, paclitaxel, or chronic constriction injury (CCI)
of the sciatic nerve (21,31e33). Tramadol, duloxetine and amitrip-
tyline inhibit serotonin and noradrenaline reuptake, besides, tra-
madol stimulates m opioid receptors. The anti-allodynic effects of
these agents may be due to their known actions in activating the
descending pain inhibitory system. However, although amitriptyline
also has same action, a single administration of amitriptyline had no
effect on bortezomib-induced mechanical allodynia. Moreover, we
found that repeated administration of amitriptyline had no analgesic
effect on the bortezomib-induced pain behavior after the develop-
ment of neuropathy (data not shown). Therefore, it is possible that
mechanisms other than the descending pain inhibitory systems are
involved in analgesic effect of duloxetine.
In our study, single administration of pregabalin (3 mg/kg) and
mexiletine (100 mg/kg) exerted anti-allodynic effects on
bortezomib-induced mechanical allodynia. Anti-allodynic effects of
these agents have been reported in animal models of neuropathy
induced by oxaliplatin, paclitaxel or spinal nerve ligation (20,31,33).
Pregabalin and mexiletine have inhibitory effects on Ca2þ channels
and Naþ channels, respectively. It is well known that Naþ and Ca2þ
channels regulate the release of pain-related neurotransmitters,
including glutamate and substance P. Therefore, the anti-allodynic
effects of these agents are thought to be due to the inhibition of
Naþ and Ca2þ channels. It has been reported that intra-
cerebroventricular injection of pregabalin reduces peripheral nerve
injury-induced painful neuropathy and increases spinal noradrena-
line turnover in mice, indicating that pregabalin produces analgesic
effects that involve the descending noradrenergic system (34).
Moreover, anti-allodynic effect of gabapentin on bortezomib-
induced mechanical allodynia is suppressed by noradrenaline, but
not serotonin, depletion in the spinal cord (15). This descending pain
inhibitory system may also be involved in the relieving effect that
pregabalin has on bortezomib-induced neuropathic pain.
The cyclooxygenase-2 (COX-2) inhibitor diclofenac did not affect
bortezomib-induced mechanical allodynia. It has previously been
shown that paclitaxel-induced mechanical allodynia is not affected
by the COX-2 inhibitors diclofenac, indomethacin, or celecoxib (33).
Thus, COX-2 inhibitors do not appear to improve BIPN.
In conclusion, the present study has characterized pain behav-
iors and pathological changes in the rat model of peripheral neu-
ropathy induced by bortezomib. It indicates that axonal
degeneration of the sciatic nerve is involved in BIPN. Moreover, our
data reveal that some analgesic drugs and adjuvants are effective in
the relief of painful neuropathy induced by bortezomib, and that
these drugs may improve the welfare of patients with multiple
myeloma who are experiencing the adverse neurological effects of
bortezomib chemotherapy.
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